EyePoint (EYPT) Income towards Parent Company (2010 - 2026)
EyePoint (EYPT) reported Income towards Parent Company of -$120.2 million for Q1 2026, down 129.33% on a YoY basis from $409.9 million in Q1 2025, and down 77.79% sequentially from -$67.6 million in Q4 2025.
EyePoint (EYPT) Income towards Parent Company (2010 - 2026) Analysis & Trends
EyePoint (EYPT) has 17 years of Income towards Parent Company data on file, last reported at -$120.2 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company fell 129.33% year-over-year to -$120.2 million; the trailing twelve-month figure through Mar 2026 stood at -$307.0 million (down 99.33% YoY), and the FY2025 full-year result was -$232.0 million, down 77.25% from the prior year.
- Income towards Parent Company fell to -$120.2 million in Q1 2026, from -$67.6 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$16.3 million in Q4 2023 to a low of -$120.2 million in Q1 2026.
- A 5-year average of -$53.2 million and a median of -$44.4 million in 2022 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company tumbled 643.39% in 2022 and jumped 72.55% in 2023, its largest moves.
- Tracing EYPT's Income towards Parent Company over 5 years: stood at -$44.4 million in 2022, then surged by 63.2% to -$16.3 million in 2023, then plunged by 153.5% to -$41.4 million in 2024, then plunged by 63.31% to -$67.6 million in 2025, then tumbled by 77.79% to -$120.2 million in 2026.
- Business Quant data shows EYPT's Income towards Parent Company at -$120.2 million in Q1 2026, -$67.6 million in Q4 2025, and -$59.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | EyePoint | 1.07 Mn | -221.48 Mn | 168,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -120.20 Mn |
| Dec 31, 2025 | -67.61 Mn |
| Sep 30, 2025 | -59.73 Mn |
| Jun 30, 2025 | -59.43 Mn |
| Mar 31, 2025 | -52.42 Mn |
| Dec 31, 2024 | -41.40 Mn |
| Sep 30, 2024 | -29.36 Mn |
| Jun 30, 2024 | -30.83 Mn |
| Mar 31, 2024 | -98.09 Mn |
| Dec 31, 2023 | -16.33 Mn |
| Sep 30, 2023 | -24.84 Mn |
| Jun 30, 2023 | -35.03 Mn |
| Mar 31, 2023 | -22.31 Mn |
| Dec 31, 2022 | -44.38 Mn |
| Sep 30, 2022 | -90.48 Mn |
| Jun 30, 2022 | -91.85 Mn |
| Mar 31, 2022 | -19.53 Mn |
| Dec 31, 2021 | -19.92 Mn |
| Sep 30, 2021 | -16.70 Mn |
| Jun 30, 2021 | -12.36 Mn |